| Primary information |
|---|
| sequence ID | Seq_2541 |
| Peptide sequence | GDFLAEGGGVR |
| CancerPDF_ID | CancerPDF_ID4, CancerPDF_ID644, CancerPDF_ID1022, CancerPDF_ID1212, CancerPDF_ID8506, CancerPDF_ID9657, CancerPDF_ID11457, |
| PMID | 16896061,19795908,16395409,21136997,23667664,21533267,26992070 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Serum,Serum,Serum |
| M/Z | 1077.53,539.27,1077.53,1076.52507,1076.53,539.25,NA |
| Charge | 1,2,1,1,1,2,NA |
| Mass (in Da) | 1077.53,NA,NA,NA,1078.17,NA,1077.53618 |
| fdr | NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,NA,1.49,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID4, CancerPDF_ID644, CancerPDF_ID1022, CancerPDF_ID1212, CancerPDF_ID8506, CancerPDF_ID9657, CancerPDF_ID11457, |
| p-Value | 1.00E-05,NA,1.97E-14,1.34E-04,NA,4.10E-15,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT,MASCOT,SEQUEST and Maxquant |
| Length | 11,11,11,11,11,11,11 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Melanoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
| Regulation | NA,NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.54, 0.5 and 0.97 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal,NA,Differentially expressed between Lung cancer vs control,"Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,na |
| Sensitivity | 95% on independent dataset,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,0.693,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 462581
|